Announcements
Takara Bio USA, Inc. (formerly Clontech Laboratories, Inc.), a wholly owned subsidiary of Takara Bio Inc., develops, manufactures, and distributes a wide range of life science research reagents under the Takara, Clontech, and Cellartis brands. To keep you up to date with the latest happenings at Takara Bio USA, we have compiled our recent announcements and press releases below.
High-throughput epigenetic profiling made possible in single cells with ICELL8 technology
Date: March 18, 2019
Categories: Press release
Researchers from Steven Henikoff's laboratory (Fred Hutchinson Cancer Research Center) have developed a novel epigenomic method, CUT&Tag (Cleavage Under Targets and Tagmentation), for high-throughput profiling of chromatin components in single cells on the ICELL8 Single-Cell System.
Takara Bio congratulates Dr. Christian Hoppmann on CPSA Innovator Award
Date: October 31, 2018
Categories: Announcement
We are pleased and excited to announce that Dr. Christian Hoppmann, Research Scientist at Takara Bio USA, Inc., was awarded an Innovator Award at CPSA USA 2018 following his presentation on Capturem technology.
Takara Bio launches industry-first CMO services for clinical-grade human embryonic stem cell derivation and banking
Date: October 5, 2018
Categories: Announcement
We are excited to be recognized in an article published by the stem cell industry blog BioInformant as the first company in the world to offer contract manufacturing services for the derivation and banking of human embryonic stem cells (hESCs) under GMP conditions.
A high-throughput single-cell ATAC-seq method developed by Stanford University now available on the SMARTer ICELL8 Single-Cell System from Takara Bio USA, Inc.
Date: September 18, 2018
Categories: Press release
Researchers from William Greenleaf's laboratory (Stanford University) have collaborated with TBUSA to develop a high-throughput single-cell ATAC-seq (assay for transposition of accessible chromatin) method on the SMARTer ICELL8 Single-Cell System.
Takara Bio products are now available on Amazon Business
Date: July 30, 2018
Categories: Announcement
Our products can now be purchased on Amazon using a business account.
Takara Bio granted manufacturing license from the Swedish Medical Product Agency for clinical-grade human embryonic stem cell line derivation and banking
Date: July 25, 2018
Categories: Press release
Takara Bio announced today that the Medical Products Agency ("MPA"), the Swedish national authority responsible for regulation and surveillance of the development, manufacturing and marketing of drug and other medical products, granted a manufacturing license for derivation and banking of human embryonic stem (hES) cells to be produced under GMP conditions at the state-of-the-art laboratory located in Göteborg, Sweden, within Takara Bio Europe's facility.
Takara Bio strengthens its IP position on single cell RNA-seq
Date: July 18, 2018
Categories: Press release
Takara Bio USA, Inc., (TBUSA, formerly Clontech Laboratories, Inc.), a wholly owned subsidiary of Takara Bio Inc., is proud to announce that patent JP6336080B—covering the Smart-seq2 method, developed by Rickard Sandberg and exclusively licensed to TBUSA by the Ludwig Institute—has been awarded by the Japan Patent Office.
About our new website
Date: July 3, 2018
Categories: Announcement
Takara Bio is pleased to announce the launch of our newly redesigned website. Its expanded features include a revamped homepage, enhanced search, improved responsiveness, and expanded learning resources.
Takara Bio announces launch of beta cell differentiation service
Date: May 17, 2018
Categories: Press release
Mountain View, CA—May 17, 2018—The Takara Bio Group, the leading provider of human stem cell differentiation services globally, has launched the Cellartis Directed Differentiation to Beta Cells Service for the delivery of high-quality, custom human induced pluripotent stem cell (hiPSC)-derived beta cells for diabetes research and metabolic disease modeling.
SMARTer ICELL8 technology aids in single-nuclei sequencing of triple-negative breast cancer to uncover chemoresistance evolution
Date: May 8, 2018
Categories: Press release
Mountain View, CA—May 8, 2018—A recent study including single-cell transcriptome analysis has revealed an evolutionary model of chemoresistance in triple-negative breast cancer (TNBC) patients. This groundbreaking work, led by Professor Nicholas Navin (The University of Texas MD Anderson Cancer Center), was published in the May issue of Cell and utilized Takara Bio’s SMARTer ICELL8 single-cell automation platform.
Takara Bio USA, Inc.
United States/Canada: +1.800.662.2566 • Asia Pacific: +1.650.919.7300 • Europe: +33.(0)1.3904.6880 • Japan: +81.(0)77.565.6999
FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. © 2023 Takara Bio Inc. All Rights Reserved. All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Certain trademarks may not be registered in all jurisdictions. Additional product, intellectual property, and restricted use information is available at takarabio.com.
